Role of transgene regulation in ex vivo lentiviral correction of artemis deficiency

Human Gene Therapy

Volumn 26, Issue 4, 2015, Pages 232-243

  Multhaup, Megan M ^a   Podetz Pedersen, Kelly M ^a   Karlen, Andrea D ^a   Olson, Erik R ^b   Gunther, Roland ^a   Somia, Nikunj V ^a   Blazar, Bruce R ^a   Cowan, Morton J ^c   McIvor, R Scott ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Discovery Genomics Inc ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIS; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; ELONGATION FACTOR 1ALPHA; ENDONUCLEASE; LENTIVIRUS VECTOR; PHOSPHOGLYCERATE KINASE; UNCLASSIFIED DRUG; DCLRE1C PROTEIN, MOUSE; NUCLEAR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTEMIS DEFICIENCY; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; GENE CONTROL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPH NODE; MOUSE; NONHUMAN; PROMOTER REGION; SEVERE COMBINED IMMUNODEFICIENCY; SPLEEN; T LYMPHOCYTE; THYMUS; WILD TYPE; 3T3 CELL LINE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DEFICIENCY; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE; SCID MOUSE; TRANSCRIPTION INITIATION; TRANSGENE;

ANIMALIA; MURINAE;

ANIMALS; ENDONUCLEASES; GENETIC THERAPY; HEK293 CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENTIVIRUS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, SCID; NIH 3T3 CELLS; NUCLEAR PROTEINS; SEVERE COMBINED IMMUNODEFICIENCY; TRANSCRIPTIONAL ACTIVATION; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84928481340     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.062     Document Type: Article

References (44)

1. Moshous D, Li L, Chasseval R, et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Hum Mol Genet 2000;9:583-588.
2. van Gent DC, McBlane JF, Ramsden DA, et al. Initiation of V(D)J recombinations in a cell-free system by RAG1 and RAG2 proteins. Curr Top Microbiol Immunol 1996;217:1-10.
3. Geng L, Zhang X, Zheng S, et al. Artemis links ATM to G2/M checkpoint recovery via regulation of Cdk1-cyclin B. Mol Cell Biol 2007;27:2625-2635.
4. Morio T, and Kim H. Ku, Artemis, and ataxia-telangiectasia- mutated: signalling networks in DNA damage. Int J Biochem Cell Biol 2008;40:598-603.
5. Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombinationprotein, is mutated in human severe combined immune deficiency. Cell 2001;105:177-186.
6. Qasim W, Gaspar HB, and Thrasher AJ. Progress and prospects: gene therapy for inherited immunodeficiencies. Gene Ther 2009;16:1285-1291.
7. Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA nonidentical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. J Pediatr 1999; 134:740-748.
8. O'Marcaigh AS, Desantes K, Hu D, et al. Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans. Bone Marrow Transplant 2001;27:703-709.
9. Aiuti A, and Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 2009;682-689. DOI: 10.1182/asheducation- 2009.
10. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-672.
11. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413.
12. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364: 2181-2187.
13. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-458.
14. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363:355-364.
15. Hacein-Bey-Abina S, Fischer A, and Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 2002;76:295-298.
16. Mostoslavsky G, Fabian AJ, Rooney S, et al. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A 2006;103:16406-16411.
17. Benjelloun F, Garrigue A, Demerens-de Chappedelaine C, et al. Stable and functional lymphoid reconstitution in artemis- deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol Ther 2008; 16:1490-1499.
18. Multhaup M, Karlen AD, Swanson DL, et al. Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer. Hum Gene Ther 2010;21: 865-875.
19. Multhaup MM, Gurram S, Podetz-Pedersen KM, et al. Characterization of the human artemis promoter by heterologous gene expression in vitro and in vivo. DNA Cell Biol 2011;30:751-761.
20. Xiao Z, Dunn E, Singh K, et al. A non-leaky Artemisdeficient mouse that accurately models the human severe combined immune deficiency phenotype, including resistance to hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:1-11.
21. Agarwal S, Nikolai B, Yamaguchi T, et al. Construction and use of retroviral vectors encoding the toxic gene barnase. Mol Ther 2006;14:555-563.
22. Wilber A, Frandsen JL, Wangensteen KJ, et al. Dynamic gene expression after systemic delivery of plasmid DNA as determined by in vivo bioluminescence imaging. Hum Gene Ther 2005;16:1325-1332.
23. Gori JL, Podetz-Pedersen K, Swanson D, et al. Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase. J Pharmacol Exp Ther 2007;322:989-997.
24. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-875.
25. Dummer W, Ernst B, Leroy E, et al. Autologous regulation of naive T cell homeostasis within the T cell compartment. J Immunol 2001;166:2460-2468.
26. Hacein-Bey-Abina S, Garrigue A,Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142.
27. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118:3143-3150.
28. Amorosi S, Russo I, Amodio G, et al. The cellular amount of the common gamma-chain influences spontaneous or induced cell proliferation. J Immunol 2009;182:3304-3309.
29. Ma Y, Pannicke U, Schwarz K, et al. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002;108:781-794.
30. Dudasova Z, and Chovanec M. Artemis, a novel guardian of the genome. Neoplasma 2003;50:311-318.
31. Bonatto D, Revers LF, Brendel M, et al. The eukaryotic Pso2/Snm1/Artemis proteins and their function as genomic and cellular caretakers. Braz J Med Biol Res 2005;38:321-334.
32. Britton S, Frit P, Biard D, et al. ARTEMIS nuclease facilitates apoptotic chromatin cleavage. Cancer Res 2009; 69:8120-8126.
33. Jacob J, Kelsoe G, Rajewsky K, et al. Intraclonal generation of antibody mutants in germinal centres. Nature 1991; 354:389-392.
34. Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation- induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
35. Petersen S, Casellas R, Reina-San-Martin B, et al. AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching. Nature 2001;414: 660-665.
36. Lieber MR, Ma Y, Pannicke U, et al. The mechanism of vertebrate nonhomologous DNA end joining and its role in V(D)J recombination. DNA Repair (Amst) 2004;3:817-826.
37. Pan-Hammarstrom Q, Jones AM, Lahdesmaki A, et al. Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med 2005;201:189-194.
38. Gennery AR. Primary immunodeficiency syndromes associated with defective DNA double-strand break repair. Br Med Bull 2006;77-78:71-85.
39. Watanabe D, Suda T, and Nagata S. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int Immunol 1995;7:1949-1956.
40. Zaheen A, Boulianne B, Parsa JY, et al. AID constrains germinal center size by rendering B cells susceptible to apoptosis. Blood 2009;114:547-554.
41. Carsetti R, Kohler G, and Lamers MC. Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med 1995;181:2129-2140.
42. Loder F, Mutschler B, Ray RJ, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999;190:75-89.
43. Carsetti R. Characterization of B-cell maturation in the peripheral immune system. Methods Mol Biol 2004;271: 25-35.
44. Martensson IL, Almqvist N, Grimsholm O, et al. The pre- B cell receptor checkpoint. FEBS Lett 2010;584:2572-2579.